Valuation: ValiRx plc

Market Cap 24.88L 33.33L 29.16L 26.89L 47.23L 32Cr 48.01L 3.22Cr 1.26Cr 16Cr 1.25Cr 1.22Cr 54Cr P/E 2023
-2.94x
P/E 2024 -0.53x
Enterprise Value 9L 12.65L 11.06L 10.2L 17.92L 12Cr 18.22L 1.22Cr 47.9L 5.93Cr 47.48L 46.45L 21Cr EV / Sales 2023
61,29,41,875x
EV / Sales 2024 2,72,64,249x
Free-Float
93.4%
Yield 2023 *
-
Yield 2024 -
1 day-6.67%
1 week-12.50%
Current month-12.50%
1 month-22.22%
3 months-54.84%
6 months-61.64%
Current year-58.21%
1 week 0.13
Extreme 0.13
0.17
1 month 0.13
Extreme 0.13
0.19
Current year 0.13
Extreme 0.13
0.48
1 year 0.13
Extreme 0.13
0.85
3 years 0.13
Extreme 0.13
15
5 years 0.13
Extreme 0.13
65
10 years 0.13
Extreme 0.13
1,436.25
Manager TitleAgeSince
Chief Executive Officer 55 12/08/2024
Director of Finance/CFO 81 -
Chief Tech/Sci/R&D Officer - 27/03/2025
Director TitleAgeSince
Director/Board Member 81 01/09/2006
Chairman 59 25/07/2024
Director/Board Member 55 12/08/2024
Date Insider Type Main position Quantity % Market Cap.
04/03Buy

Chief Executive Officer

10,00,000 0.1346%
18/22/18Free

Director

75,000 0.0832%
18/22/18Free

Director

75,000 0.0832%
Change 5-day change 1-year change 3-year change Capi.($)
-6.67%-12.50%-74.55%-98.07% 15.43L
-3.41%-7.29%+58.67%+119.06% 5.7TCr
+4.91%-0.19%+73.70%+92.14% 5.36TCr
-3.84%+2.43%+18.20%+460.05% 2.56TCr
-1.77%-2.47%-19.58%-14.73% 2.35TCr
+2.43%+1.06%+47.70%-0.11% 1.94TCr
-3.65%+1.18%+35.57%-26.01% 1.81TCr
-6.84%+2.18%+203.03%+348.11% 1.65TCr
+8.74%+3.51%+53.81% - 1.41TCr
-1.67%+1.24%+24.46%+194.81% 1.44TCr
Average -1.16%-0.43%+42.10%+119.47% 2.42TCr
Weighted average by Cap. -0.42%-0.31%+55.00%+136.88%

Financials

2023 2024
Net sales 0.01 0.01 0.01 0.01 0.02 1.23 0.02 0.12 0.05 0.6 0.05 0.05 2.09 0.05 0.07 0.06 0.05 0.09 6.37 0.1 0.64 0.25 3.13 0.25 0.24 10.83
Net income -20.38L -27.3L -23.88L -22.02L -38.68L -26Cr -39.32L -2.64Cr -1.03Cr -13Cr -1.02Cr -1Cr -44Cr -19.16L -25.67L -22.45L -20.7L -36.36L -24Cr -36.97L -2.48Cr -97.2L -12Cr -96.35L -94.27L -42Cr
Net Debt -2L -2L -2L -2L -3L -1.95Cr -3L -19.75L -8L -95.84L -8L -8L -3.32Cr -15.44L -20.69L -18.1L -16.69L -29.31L -20Cr -29.8L -2Cr -78.35L -9.7Cr -77.66L -75.98L -34Cr
Logo ValiRx plc
ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.
Employees
14
Date Price Change Volume
10/26/10 GBX 0.1450 -3.33% 12,73,62,395
09/26/09 GBX 0.1500 -3.23% 1,96,00,569
08/26/08 GBX 0.1550 0.00% 2,265
07/26/07 GBX 0.1550 0.00% 4,602
06/26/06 GBX 0.1550 -3.13% 31,54,434

Annual profits - Rate of surprise